- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04423484
Therapeutic Recommendations for Nephroblastoma (GFANEPHRO20)
September 11, 2023 updated by: French Africa Pediatric Oncology Group
Therapeutic Recommendations for the Treatment of Children With Nephroblastoma in Africa.
The study is based on results form 2 previous studies carried out by the GFAOP.
The aim of this study is to evaluate the capacity of units to follow the recommendations in the protocol.
Study Overview
Detailed Description
The study is based on results form 2 previous studies carried out by the GFAOP.
This study aims to evaluate the capacity of units to follow the recommendations in the protocol.
It will look mainly at treatment compliance and outcome for the children treated.
The study will also evaluate the improvement in treatment compliance and reporting.
This work will help the group to evaluate future needs in participating units and help us adapt treatment programmes to local conditions.
Study Type
Observational
Enrollment (Estimated)
1000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: BRENDA Ms MALLON, MSc
- Phone Number: 0033142115411
- Email: brenda.mallon@gustaveroussy.fr
Study Locations
-
-
-
Ouagadougou, Burkina Faso
- Recruiting
- Centre Hospitalier Universitaire Pédiatrique Charles De Gaulle
-
Contact:
- Sonia Ms Kaboret, Dr
-
Contact:
- kawajo200046@gmail.com
-
-
-
-
-
Kinshasa, Congo, The Democratic Republic of the, BP 12 KIN XI
- Recruiting
- CUK (Cliniques Universitaires de Kinshasa)
-
Contact:
- Aléine BUDIONGO, DR
- Phone Number: +(243)99 81 53 133.
- Email: albudiongo@gmail.com
-
Lubumbashi, Congo, The Democratic Republic of the, BP 1825
- Recruiting
- Cliniques Universitaires de Lubumbashi (CUL)
-
Contact:
- Robert LUKAMBA, DR
- Phone Number: 00(243) 814024633
- Email: robertlukamba@yahoo.fr
-
-
-
-
-
Abidjan, Côte D'Ivoire
- Recruiting
- CHU de Treichville à ABIDJAN
-
Contact:
- Line Guei COUITCHERE, MD
-
-
-
-
-
Antananarivo, Madagascar
- Recruiting
- HJRA, Hôpital universitaire Joseph Ravoahangy Andrianavalona
-
Contact:
- Mbola Mr RAKOTOMAHEFA, Dr
- Email: mahefambola@yahoo.fr
-
Principal Investigator:
- Mbola RAKOTOMAHEFA, Dr
-
-
-
-
-
Bamako, Mali
- Recruiting
- CHU Gabriel Touré (HGT)
-
Contact:
- Boubacar TOGO, PROFESSEUR
- Phone Number: +223 66 74 29 04
- Email: boubacar.togo@gfaop.org
-
-
-
-
-
Dakar, Senegal
- Recruiting
- Hôpital Aristide Le Dantec, Avenue Pasteur, BP 3001
-
Contact:
- DIAGNE AKONDE Fatou-Binetou, Dr
- Phone Number: 00(221)77 637 40 63
- Email: fabakonde@gmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 months to 18 years (Child, Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
All children with local Nephroblastoma in all participating units
Description
Inclusion Criteria:
Unilateral Nephroblastoma Tumor Not previously treated The general health of the child will permit treatment.
.
Exclusion Criteria:
Bilateral Nephroblastoma tumor Previously treated Disease too advanced Doubt concerning the diagnosis Treatment Refusal
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Children with Nephroblastoma
All children coming into the participating units with suspected Nephroblastoma.
|
Clinical stage, treatment given and observations of toxicity if any, outcome following treatment and follow up.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of the number of cases with local disease.
Time Frame: 5 years
|
By evaluating the initial clinical reports and later histological reports to confirm the stage and the diagnosis.
|
5 years
|
Evaluation of the number of cases with stage IV disease.
Time Frame: 5 Years
|
By evaluating the initial clinical reports and later histological reports to confirm the stage.
|
5 Years
|
Evaluating the treatment given.
Time Frame: 5 Years
|
Comparison of treatment given and recommended treatment.
|
5 Years
|
Evaluating the follow up after treatment.
Time Frame: 5 Years
|
How many children alive or dead after treatment
|
5 Years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Why has treatment failed
Time Frame: 5 years
|
look at precision of reporting by comparing reports (histological and surgical)
|
5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Fatou Binetou Ms DIAGNE AKONDE, Dr, French Africa Pediatric Oncology Group
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 1, 2020
Primary Completion (Estimated)
December 31, 2025
Study Completion (Estimated)
September 30, 2026
Study Registration Dates
First Submitted
June 4, 2020
First Submitted That Met QC Criteria
June 6, 2020
First Posted (Actual)
June 9, 2020
Study Record Updates
Last Update Posted (Actual)
September 13, 2023
Last Update Submitted That Met QC Criteria
September 11, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Genetic Diseases, Inborn
- Kidney Neoplasms
- Neoplastic Syndromes, Hereditary
- Neoplasms, Complex and Mixed
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Wilms Tumor
Other Study ID Numbers
- GFANEPHRO2020
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nephroblastoma
-
Federal Research Institute of Pediatric Hematology...RecruitingNephroblastoma (Wilms Tumour)Russian Federation
-
Shengjing HospitalNot yet recruiting0.5-14 Year Old Children With NephroblastomaChina
-
Assistance Publique - Hôpitaux de ParisCompletedNephroblastoma With Vena Cava ThrombosisFrance
-
National Cancer Institute (NCI)CompletedNeuroblastoma | NephroblastomaUnited States
-
Universitätsklinikum Hamburg-EppendorfRecruitingPsychosocial Situation of Children With Rare Solid Abdominal Tumors and Their Families (PsyRareCare)Neuroblastoma | Hepatoblastoma | NephroblastomaGermany
-
University Hospital, AngersUnknownAcute Lymphoblastic Leukemia | Nephroblastoma | Hepatic Veno-Occlusive DiseaseFrance
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Rhabdoid Tumor | Wilms Tumor | Nephroblastoma | Malignant Peripheral Nerve Sheath Tumors | MPNST | XPO1 Gene MutationUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)RecruitingRenal Cell Carcinoma | Wilms Tumor | Clear Cell Sarcoma of the Kidney | Papillary Renal Cell Carcinoma | Kidney Medullary Carcinoma | Diffuse Hyperplastic Perilobar Nephroblastomatosis | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Renal Cell Carcinoma Associated With Xp11.2 Translocations... and other conditionsUnited States, Canada, Puerto Rico, Australia, New Zealand, Israel, Switzerland
Clinical Trials on Data collection
-
Care Management PlusCompletedHealth Information Technology | Nurse Based Care ManagementUnited States
-
University Hospital, Basel, SwitzerlandRecruitingInfections With CPBSwitzerland
-
M.D. Anderson Cancer CenterUnknownPediatric CancerUnited States
-
GlaxoSmithKlineCompletedInfections, StreptococcalRomania, Slovenia, Poland, Lithuania, Estonia
-
GCS Ramsay Santé pour l'Enseignement et la RechercheNot yet recruiting
-
Assistance Publique - Hôpitaux de ParisRecruiting
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Women and Infants Hospital of Rhode IslandTerminated
-
Centre Hospitalier Universitaire DijonCompletedCoronary Artery Bypass Graft | Anomalies in Glucose MetabolismFrance